Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Altimmune Inc
(NQ:
ALT
)
6.300
+0.280 (+4.65%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,872,018
Open
6.020
Bid (Size)
6.260 (6)
Ask (Size)
6.290 (58)
Prev. Close
6.020
Today's Range
5.940 - 6.345
52wk Range
2.090 - 14.84
Shares Outstanding
71,070,951
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
Today 14:11 EDT
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.
Via
Benzinga
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
September 17, 2024
Telemedicine once seemed like it was going to revolutionize healthcare.
Via
The Motley Fool
Performance
YTD
-40.11%
-40.11%
1 Month
-12.13%
-12.13%
3 Month
-20.25%
-20.25%
6 Month
-21.15%
-21.15%
1 Year
+141.38%
+141.38%
More News
Read More
Decoding 4 Analyst Evaluations For Altimmune
August 22, 2024
Via
Benzinga
3 Promising Biotech Stocks for the Long-Term: August 2024
August 13, 2024
Via
InvestorPlace
The 7 Best Under $10 Stocks to Buy in August 2024
August 11, 2024
Via
InvestorPlace
ALT Stock Earnings: Altimmune Misses EPS for Q2 2024
August 08, 2024
Via
InvestorPlace
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year
August 09, 2024
Via
The Motley Fool
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
August 07, 2024
From
CytoSorbents
Via
GlobeNewswire
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.
August 02, 2024
Via
The Motley Fool
ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
July 30, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
July 20, 2024
Via
The Motley Fool
3 Undervalued Biotech Stocks With Breakout Potential
July 19, 2024
Via
InvestorPlace
Forget Boring Diversification! 3 Wild-Card Stocks to Spice Up Your Portfolio
July 17, 2024
Via
InvestorPlace
Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics
July 10, 2024
Via
The Motley Fool
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
July 09, 2024
Via
MarketBeat
7 Bullish Stock Picks With the Potential to Turn $5K Into $50K
July 09, 2024
Via
InvestorPlace
The 7 Best Under $10 Stocks to Buy in July 2024
July 06, 2024
Via
InvestorPlace
MarketBeat Week in Review – 7/1 - 7/5
July 06, 2024
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intel, Harbor Diversified, Altimmune, and Sprout Social and Encourages Investors to Contact the Firm
July 04, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
July 04, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
ALTIMMUNE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Altimmune, Inc. and Encourages Investors to Contact the Firm
July 03, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Altimmune, Inc. (ALT)
July 03, 2024
From
Law Offices of Frank R. Cruz
Via
Business Wire
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
July 03, 2024
Via
MarketBeat
Exposures
Product Safety
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
July 02, 2024
Via
MarketBeat
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
July 01, 2024
Via
MarketBeat
Exposures
Product Safety
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.